Hgf preparation suitable for treatment of nervous diseases
CA2756851A1
Therapeutic agent for cancer having reduced sensitivity to molecular target drug and pharmaceutical composition for enhancing sensitivity to molecular target drug
WO2010041716A1
Promoter for regeneration of tendon-bone junction tissue or ligament-bone junction tissue
WO2010008023A1
Bone elongation promoter
WO2009087485A2
Topical compositions for delivery of proteins and peptides
WO2008150023A2
Method for producing antagonist of growth factor
JP2009159883A
New gene therapy agent
JP2008007514A
Medicine comprising nk4 gene or recombinant nk4 gene
EP2014676A1
Hgf precursor protein mutant and activated form thereof
CA2649820A1
Agent for treating polyglutamine aggregation-caused disease or suppressing onset thereof
WO2008102452A1
Hgf preparation
WO2006132251A1
Prophylactic/therapeutic agent for adult t cell leukemia
CA2594629A1
Fibrosis inhibitor for implanted organ
EP1731131A1
Hgf production accelerator containing heparin-like oligosaccharide
US7807177B2
Segment of glycosylation-deficient HGFalpha-chain
CA2541603A1
Agent for improving mental disorders
JP2005306749A
Hgf-containing preserving liquid for organ
GB0519079D0
Asthma preparation
WO2004108144A1
Cell-containing preparations
JP2003250549A
Pharmaceutical preparation made from nk4 gene or recombinant nk4 protein
